This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive ® has been developed through a 13-year collaboration between the world’s largest vaccine manufacturer Serum Institute of India Pvt.
Moderna has filed patent infringement lawsuits alleging that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty ® infringes patents Moderna filed between 2010 and 2016 covering its foundational messenger RNA (mRNA) technology. ” But why sue now? .” ” But why sue now?
The Nobel Assembly has awarded Hungarian biochemist Katalin Karikó and US immunologist Drew Weissman the Nobel Prize in Physiology or Medicine 2023 for their breakthrough findings in RNA vaccine development. The discovery was critical for developing effective mRNA vaccines during the COVID-19 pandemic.
Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge.
On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. What’s more, VAX-24 achieved a higher immune response to 16 of the 20 serotypes it shares with Prevnar 20.
While restrictions on travel could prevent coronavirus transmission in the short term, digital passports showing COVID-negative and vaccination status may help reopen airports and other badly hit areas of the economy, reports Richard Staines. But could digital immunity passports be the answer?
Pharmaceutical companies have been working on developing vaccines and other prophylactics for respiratory syncytial virus (RSV) since its discovery in 1956. Despite strong efforts and scientific advances, a safe and effective vaccine for RSV has yet to be approved for any patient population.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.
The next generation RNA therapeutics and RNA vaccines pipeline currently features the presence of more than 20 circular RNA therapeutics and vaccines, being developed across initial stages of drug development (discovery and preclinical).
Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines. Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These can serve as an important component of a vaccine.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.
Its platform has capabilities to be used in combination with CAR-T and other cell therapies to overcome poor immune cell infiltration, immunosuppressive properties of tumour microenvironment, and systematic toxicity issues. The company has an operational presence in the US and the UK (headquartered in Abingdon, Oxfordshire, UK).
In the last few years, the first generation of cell therapies has offered a powerful new way of treating blood cancers, with CAR-T technology reprogramming patients’ immune system to fight cancer. The post After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer appeared first on.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Hoffmann-La Roche is the leading patent filer in the peptide nano-particle conjugates space.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Hoffmann-La Roche is the leading patent filer of oxazole derivatives-based cancer drug compositions.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.
The company’s product portfolio comprises two platforms: Virax Immune, a new-Covid-19 test detecting the T-Cell immune response to the SARS-Cov-2 virus and ViraxClear, a platform to sell a range of highly accurate diagnostic test kits and machines. Founded Year: 2010 No. Funding Value: $7.7M Founded Year: 2021 No.
Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases. Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines.
Noteworthy cases were the inadvertent introduction of grade 316L stainless steel into Moder-na’s COVID-19 vaccine by the outsourced manufacturer (ROVI Pharma Industrial Services S. In the Moderna COVID-19 vaccine contamination case, three lots of the five lots affected, totaling 1.63 5 (2010): 2209–2218. link] 12 MacDonald, M.
It is a comprehensive stool-based test that addresses a wide range of microbial targets (bacteria, opportunistic organisms, viruses, parasites, fungi, and normal flora), as well as immune and digestive markers. This can allow the body’s immune system to attack the thyroid (or elsewhere) versus the infection. [17]
Ken Perez VP of Healthcare Policy Omnicell The Democrats’ recent sweep of the United States Senate Georgia runoff elections means the Democrats will control both chambers of Congress as well as the White House for the first time since 2010.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content